InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Voyager Therapeutics, Inc.

VYGR Clue Score26
United States Fiscal year ends December CIK 0001640266
$2.45 +3.38% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $2.45 −48.96% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Revenue14.2Operating income−41.3Net income−40.2Fiscal year 2017Revenue10.1 −28.7%Operating income−71.9Net income−70.7Fiscal year 2018Revenue7.6 −24.8%Operating income−91.1Net income−88.3EPS, diluted−2.75Fiscal year 2019Revenue104.4 +1,270.1%Operating income−51.7Net income−43.6EPS, diluted−1.21Fiscal year 2020Revenue171.1 +63.9%Operating income27.4Net income36.7EPS, diluted0.98Fiscal year 2021Revenue37.4 −78.1%Operating income−73.6Net income−71.2 −293.8%EPS, diluted−1.89 −292.9%Fiscal year 2022Revenue40.9 +9.3%Operating income−50.8Net income−46.4EPS, diluted−1.21Fiscal year 2023Revenue250.0 +511.2%Operating income122.0Net income132.3EPS, diluted2.97Fiscal year 2024Revenue80.0 −68.0%Operating income−83.3Net income−65.0 −149.1%EPS, diluted−1.13 −138.0%Fiscal year 2025Revenue40.4 −49.5%Operating income−131.8Net income−119.7EPS, diluted−2.04
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 14.2 10.1 7.6 104.4 171.1 37.4 40.9 250.0 80.0 40.4
Growth −28.7% −24.8% +1,270.1% +63.9% −78.1% +9.3% +511.2% −68.0% −49.5%
Operating income −41.3 −71.9 −91.1 −51.7 27.4 −73.6 −50.8 122.0 −83.3 −131.8
Net income −40.2 −70.7 −88.3 −43.6 36.7 −71.2 −46.4 132.3 −65.0 −119.7
Growth −293.8% −149.1%
EPS, diluted n/a n/a −2.75 −1.21 0.98 −1.89 −1.21 2.97 −1.13 −2.04
Growth −292.9% −138.0%

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2016Operating margin−290.4%Net margin−282.7%Free cash flow margin−334.1%Fiscal year 2017Operating margin−709.1%Net margin−697.6%Free cash flow margin−644.6%Fiscal year 2018Operating margin−1,195.6%Net margin−1,158.8%Free cash flow margin−265.0%Fiscal year 2019Operating margin−49.5%Net margin−41.8%Free cash flow margin39.2%Fiscal year 2020Operating margin16.0%Net margin21.5%Free cash flow margin−63.6%Fiscal year 2021Operating margin−196.8%Net margin−190.3%Free cash flow margin−147.4%Fiscal year 2022Operating margin−124.3%Net margin−113.4%Free cash flow margin−36.7%Fiscal year 2023Operating margin48.8%Net margin52.9%Free cash flow margin29.9%Fiscal year 2024Operating margin−104.1%Net margin−81.3%Free cash flow margin−23.5%Fiscal year 2025Operating margin−326.6%Net margin−296.5%Free cash flow margin−334.5%
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin −290.4% −709.1% −1,195.6% −49.5% 16.0% −196.8% −124.3% 48.8% −104.1% −326.6%
Net margin −282.7% −697.6% −1,158.8% −41.8% 21.5% −190.3% −113.4% 52.9% −81.3% −296.5%
Free cash flow margin −334.1% −644.6% −265.0% 39.2% −63.6% −147.4% −36.7% 29.9% −23.5% −334.5%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−42.5Capital expenditure−5.0Free cash flow−47.5Fiscal year 2017Operating cash flow−61.4Capital expenditure−4.0Free cash flow−65.3Fiscal year 2018Operating cash flow−15.9Capital expenditure−4.3Free cash flow−20.2Fiscal year 2019Operating cash flow48.7Capital expenditure−7.7Free cash flow40.9Fiscal year 2020Operating cash flow−96.7Capital expenditure−12.1Free cash flow−108.8 −365.7%Fiscal year 2021Operating cash flow−53.5Capital expenditure−1.6Free cash flow−55.1Fiscal year 2022Operating cash flow−12.5Capital expenditure−2.5Free cash flow−15.0Fiscal year 2023Operating cash flow77.9Capital expenditure−3.3Free cash flow74.7Fiscal year 2024Operating cash flow−15.3Capital expenditure−3.5Free cash flow−18.8 −125.2%Fiscal year 2025Operating cash flow−132.5Capital expenditure−2.6Free cash flow−135.1
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −42.5 −61.4 −15.9 48.7 −96.7 −53.5 −12.5 77.9 −15.3 −132.5
Capital expenditure −5.0 −4.0 −4.3 −7.7 −12.1 −1.6 −2.5 −3.3 −3.5 −2.6
Free cash flow −47.5 −65.3 −20.2 40.9 −108.8 −55.1 −15.0 74.7 −18.8 −135.1
Growth −365.7% −125.2%

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2016Cash36.6Shareholders’ equity135.9Fiscal year 2017Cash31.5Shareholders’ equity134.1Fiscal year 2018Cash46.9Shareholders’ equity46.4Fiscal year 2019Cash86.0Shareholders’ equity99.5Fiscal year 2020Cash104.4Shareholders’ equity154.3Fiscal year 2021Cash117.4Shareholders’ equity95.1Fiscal year 2022Cash99.0Shareholders’ equity59.0Fiscal year 2023Cash68.8Shareholders’ equity236.3Fiscal year 2024Cash71.4Shareholders’ equity299.8Fiscal year 2025Cash65.3Shareholders’ equity196.1
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 36.6 31.5 46.9 86.0 104.4 117.4 99.0 68.8 71.4 65.3
Shareholders’ equity 135.9 134.1 46.4 99.5 154.3 95.1 59.0 236.3 299.8 196.1

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
14.2 10.1 7.6 104.4 171.1 37.4 40.9 250.0 80.0 40.4
Growth −28.7% −24.8% +1,270.1% +63.9% −78.1% +9.3% +511.2% −68.0% −49.5%
42.2 62.3 64.9 119.7 108.8 73.8 60.8 92.2 127.4 134.7
13.3 19.7 33.8 36.3 35.0 37.2 31.0 35.8 35.9 37.5
−41.3 −71.9 −91.1 −51.7 27.4 −73.6 −50.8 122.0 −83.3 −131.8
Growth −368.8% −168.3%
−40.1 −70.7 −88.5 −43.6 36.7 −71.2 −46.4 133.7 −64.3 −119.6
0.1 n/a −0.2 n/a n/a n/a 0.0 1.4 0.7 0.1
−40.2 −70.7 −88.3 −43.6 36.7 −71.2 −46.4 132.3 −65.0 −119.7
Growth −293.8% −149.1%
Per share
n/a n/a −2.75 −1.21 0.99 −1.89 −1.21 3.08 −1.13 −2.04
n/a n/a −2.75 −1.21 0.98 −1.89 −1.21 2.97 −1.13 −2.04
Growth −292.9% −138.0%
n/a n/a 32.1 35.9 37.1 37.7 38.4 43.0 57.7 58.7
n/a n/a 32.1 35.9 37.3 37.7 38.4 44.6 57.7 58.7
Growth +12.0% +4.0% +0.9% +1.8% +16.2% +29.4% +1.8%

Five years in brief

Worked out from the figures above, not from a press release
  • Revenue shrank 25.1% a year over five years.
  • The diluted share count rose 57.1% in five years, which is dilution.
  • Operating margin is down 342.6 points on five years ago, at -326.6%.
  • A net loss in 8 of 10 years on file.